An interventional study of Rosuvastatin and Digoxin in Liver Cirrhosis, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Boehringer Ingelheim · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Liver Cirrhosis with a site in Germany — 24 open to participants now, 27 under way, 2 of them phase 3. Liver Cirrhosis · Germany.
Among the 82 studies in Liver Cirrhosis with a site in Germany, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2023, is one of 12 with no phase, and was the 61st registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →24 of the 82 studies in Liver Cirrhosis with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Muenster · Sites in Germany
Ages 18+
University Medical Center Groningen · Sites in Germany, Austria, Belgium and 9 more countries
Ages 18+
Hannover Medical School · Sites in Germany
Ages 18–99 · Healthy volunteers
University Hospital Freiburg · Sites in Germany
Ages 18–80
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 20 · Phase 3 8 · Phase 4 3
First in 2000; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 110 across the 43 interventional studies, 200 across the 37 observational. Of the 51 that completed or were terminated, 18 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 82 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 8 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Cirrhosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in Liver Cirrhosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis. The study measures if the approved medicines rosuvastatin, digoxin, metformin, and furosemide are processed differently in people with liver cirrhosis than in people without liver cirrhosis.
This study will help to understand how new medicines being developed are handled by the body in people with liver cirrhosis. There are 3 groups in this study: people without liver cirrhosis, people with mild liver cirrhosis, and people with moderate liver cirrhosis. All participants get 1 dose each of rosuvastatin, digoxin, metformin, and furosemide by mouth. The participants with liver cirrhosis continue their regular treatment for the condition during the study.
Participants are in the study for about 1 month. During this time, they visit the study site 4 times. For 1 of the visits, they stay overnight for 2 nights at the study site. To assess the main study endpoint, the doctors take frequent blood samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.
Inclusion criteria
Healthy subjects and F4 liver cirrhosis patients:
Either male subject, or female subject who meets any of the following criteria for a highly effective from at least 30 days before the first administration of trial medication until 30 days after trial completion:
Healthy subjects only:
F4 liver cirrhosis patients only:
Healthy subjects and F4 liver cirrhosis patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants received a single dose of the following cocktail on Day 1 after a standardized light breakfast and 280 ml of water: 0.25 milligrams (mg) digoxin as tablet, 1 mg furosemide as 0.1 milliliters (ml) oral solution, 10 mg metformin hydrochloride as 0.05 ml oral solution and 10 mg rosuvastatin as film-coated tablet.
Drug: Rosuvastatin · Drug: Digoxin · Drug: Metformin hydrochlorid · Drug: Furosemide
Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A received a single dose of the following cocktail on Day 1 after a standardized light breakfast and with 280 ml of water: 0.25 milligrams (mg) digoxin as tablet, 1 mg furosemide as 0.1 milliliters (ml) oral solution, 10 mg metformin hydrochloride as 0.05 ml oral solution and 10 mg rosuvastatin as film-coated tablet. Compensated=without any disease symptoms
Drug: Rosuvastatin · Drug: Digoxin · Drug: Metformin hydrochlorid · Drug: Furosemide
Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that met the criteria for Child-Pugh B received a single dose of the following cocktail on Day 1 after a standardized light breakfast and with 280 ml of water: 0.25 milligrams (mg) digoxin as tablet, 1 mg furosemide as 0.1 milliliters (ml) oral solution, 10 mg metformin hydrochloride as 0.05 ml oral solution and 10 mg rosuvastatin as film-coated tablet. Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome
Drug: Rosuvastatin · Drug: Digoxin · Drug: Metformin hydrochlorid · Drug: Furosemide
Rosuvastatin
Digoxin
Metformin hydrochloride
Furosemide
Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Area Under the Concentration Time Curve of Digoxin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Maximum Measured Concentration of Digoxin in Plasma (Cmax)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Area Under the Concentration Time Curve of Metformin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Maximum Measured Concentration of Metformin in Plasma (Cmax)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Area Under the Concentration Time Curve of Furosemide in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Maximum Measured Concentration of Furosemide in Plasma (Cmax)
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
The purpose of this single dose, open label study was to investigate whether the maximum concentration (Cmax) and the area under the concentration-time curve of the analyte in plasma from time point 0 to time point 24 hours (AUC0-24) values for the different components in the transporter cocktail - digoxin, furosemide, metformin and rosuvastatin are similar or different in F4 graded liver fibrosis (cirrhosis) patients on standard therapy compared to healthy participants.
| Milestone | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Started | 11 | 11 | 6 |
| Completed | 11 | 11 | 6 |
| Not completed | 0 | 0 | 0 |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| hours*nanomole/liters (h*nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) | 94.5 ± NA | 120.2 ± NA | 704.6 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| nanomole/liters (nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax) | 9.8 ± NA | 17.9 ± NA | 167.1 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| hours*nanomole/liters (h*nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Area Under the Concentration Time Curve of Digoxin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) | 8.1 ± NA | 7.8 ± NA | 7.6 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| nanomole/liters (nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Maximum Measured Concentration of Digoxin in Plasma (Cmax) | 1.7 ± NA | 1.3 ± NA | 1.4 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| hours*nanomole/liters (h*nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Area Under the Concentration Time Curve of Metformin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) | 2035.7 ± NA | 1982.8 ± NA | 1917.9 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| nanomole/liters (nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Maximum Measured Concentration of Metformin in Plasma (Cmax) | 348.0 ± NA | 303.6 ± NA | 291.0 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| hours*nanomole/liters (h*nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Area Under the Concentration Time Curve of Furosemide in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) | 238.0 ± NA | 210.1 ± NA | 275.0 ± NA |
Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.
| nanomole/liters (nmol/l) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| Maximum Measured Concentration of Furosemide in Plasma (Cmax) | 81.1 ± NA | 62.3 ± NA | 78.0 ± NA |
Collected over For AEs on-treatment period: From start of drug administration on Day 1 plus longest residual effect period for drugs in the cocktail, up to 10 days. For all-cause mortality: From start of drug administration until end of follow-up, up to 18 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Healthy Participants | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Event | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) |
|---|---|---|---|
| HeadacheNervous system disorders | 2/11 | 2/11 | 0/6 |
| Taste disorderNervous system disorders | 0/11 | 1/11 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 0/11 | 0/6 |
| NasopharyngitisInfections and infestations | 1/11 | 0/11 | 0/6 |
Treated set (TS): The treated set included all subjects who signed informed consent and were treated with at least one dose of study drug.
| Age, Continuous(Years) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) | Total |
|---|---|---|---|---|
| Mean | 58.5 ± 8.9 | 60.2 ± 11.9 | 61.2 ± 13.5 | 59.7 ± 10.8 |
| Sex: Female, Male(Participants) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) | Total |
|---|---|---|---|---|
| Female | 6 | 6 | 2 | 14 |
| Male | 5 | 5 | 4 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 11 | 6 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Healthy Participants | Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) | Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 11 | 11 | 6 | 28 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g., studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https:// www.mystudywindow.com/msw/datatransparency
Ran from Sep 2023 to primary completion in Dec 2024, 15 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 215 interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Digoxin · Furosemide